Ascendis Pharma A/S (ASND) News Today → The #1 Investment of the Decade… (From Porter & Company) (Ad) Free ASND Stock Alerts $122.80 -1.24 (-1.00%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 7:53 PM | markets.businessinsider.comAnalyst Issues ‘Buy’ Rating on Ascendis Pharma, Anticipates FDA Approval for TransCon PTHMay 16 at 12:38 PM | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) PT Raised to $140.00Morgan Stanley lifted their price objective on Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an "equal weight" rating in a research note on Thursday.May 15 at 8:01 PM | markets.businessinsider.comPositive Outlook on Ascendis Pharma with Buy Rating Amid Expected US Approval of TransCon PTHMay 15 at 8:01 PM | finance.yahoo.comFDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three MonthsMay 15 at 5:40 PM | marketbeat.com151,587 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by First Turn Management LLCFirst Turn Management LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 151,587 shares of the biotechnology companMay 15 at 10:05 AM | marketbeat.comCantor Fitzgerald Reiterates Overweight Rating for Ascendis Pharma A/S (NASDAQ:ASND)Cantor Fitzgerald reiterated an "overweight" rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a report on Wednesday.May 15 at 2:24 AM | stockhouse.comAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon(TM) PTH for Adults with HypoparathyroidismMay 14 at 4:22 PM | finance.yahoo.comUPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapyMay 14 at 4:22 PM | finance.yahoo.comUS Equity Markets Close Higher Tuesday as Producer Prices RiseMay 14 at 2:43 PM | reuters.comFDA extends review of Ascendis Pharma's hormone disorder therapyMay 14 at 2:31 PM | globenewswire.comAscendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismMay 13 at 8:30 AM | globenewswire.comSignificant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialMay 9, 2024 | marketbeat.comTimesSquare Capital Management LLC Lowers Position in Ascendis Pharma A/S (NASDAQ:ASND)TimesSquare Capital Management LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 5.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 792,945 shares of the biotechnology company's stock aMay 9, 2024 | globenewswire.comLatest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024May 8, 2024 | seekingalpha.comAn Update On Ascendis Pharma's Path To ProfitabilityMay 6, 2024 | finance.yahoo.comAscendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call TranscriptMay 4, 2024 | finance.yahoo.comAscendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 3, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $262.00 at Wells Fargo & CompanyWells Fargo & Company increased their price objective on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an "overweight" rating in a report on Friday.May 3, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday.May 2, 2024 | investorplace.comASND Stock Earnings: Ascendis Pharma Reported Results for Q1 2024May 2, 2024 | globenewswire.comAscendis Pharma Reports First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comAscendis Pharma (spons ADRs) earnings preview: what to expectApril 30, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Short Interest Up 7.5% in AprilAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 3,600,000 shares, a growth of 7.5% from the March 31st total of 3,350,000 shares. Based on an average daily volume of 348,900 shares, the short-interest ratio is currently 10.3 days.April 29, 2024 | msn.comDevelopment dedicated to bioscience, pharma moves forward in ArlingtonApril 29, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday TradingApril 26, 2024 | benzinga.comLooking Into Ascendis Pharma's Recent Short InterestApril 25, 2024 | globenewswire.comAscendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024April 25, 2024 | marketbeat.comabrdn plc Invests $17.48 Million in Ascendis Pharma A/S (NASDAQ:ASND)abrdn plc bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 138,791 shares of the biotechnology company's stock, valued at approximately $April 24, 2024 | markets.businessinsider.comUnited Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismApril 24, 2024 | markets.businessinsider.comAscendis Pharma Says UK Approves YORVIPATH For Treatment Of Adults With Chronic HypoparathyroidismApril 24, 2024 | globenewswire.comUnited Kingdom's MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismApril 24, 2024 | marketbeat.comAscendis Pharma A/S (ASND) Set to Announce Quarterly Earnings on ThursdayAscendis Pharma A/S (NASDAQ:ASND) will be releasing earnings on Thursday, April 25, Yahoo Finance reports.April 22, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Rating Reiterated by Morgan StanleyMorgan Stanley reissued an "equal weight" rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a report on Monday.April 16, 2024 | marketbeat.comSequoia Financial Advisors LLC Makes New $732,000 Investment in Ascendis Pharma A/S (NASDAQ:ASND)Sequoia Financial Advisors LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 5,811 shares of the biotechnology company's stock, valued at approximApril 15, 2024 | marketbeat.comRaymond James Financial Services Advisors Inc. Has $1.04 Million Stake in Ascendis Pharma A/S (NASDAQ:ASND)Raymond James Financial Services Advisors Inc. trimmed its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 45.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,224 sharesApril 14, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Sees Significant Increase in Short InterestAscendis Pharma A/S (NASDAQ:ASND - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 3,350,000 shares, a growth of 13.9% from the March 15th total of 2,940,000 shares. Based on an average daily trading volume, of 375,400 shares, the days-to-cover ratio is currently 8.9 days.April 14, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Position Reduced by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC lessened its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 203,172 shares of theApril 12, 2024 | benzinga.comAscendis Pharma's Options Frenzy: What You Need to KnowApril 9, 2024 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendatApril 7, 2024 | seekingalpha.comWeek In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 BillionApril 4, 2024 | benzinga.comHere's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 YearsApril 2, 2024 | msn.comRoivant announces $1.5B share buyback, positive Phase 2 dataApril 2, 2024 | finance.yahoo.comBiotech With 520% Sales Growth Nears Next Buy PointApril 2, 2024 | marketbeat.comJPMorgan Chase & Co. Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $167.00JPMorgan Chase & Co. upped their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an "overweight" rating in a research note on Tuesday.April 1, 2024 | marketbeat.comAscendis Pharma A/S's (ASND) "Overweight" Rating Reiterated at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a report on Monday.March 22, 2024 | finance.yahoo.comAre Medical Stocks Lagging AdaptHealth (AHCO) This Year?March 22, 2024 | finance.yahoo.comTwo Health Care Stocks Outperform S&P 500, Offer EntriesMarch 22, 2024 | finance.yahoo.comAscendis Pharma A/S (ASND) Rose on Positive Trial ResultsMarch 18, 2024 | marketbeat.comWells Fargo & Company Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $260.00Wells Fargo & Company lifted their price target on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an "overweight" rating in a report on Friday.March 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: aTyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND) Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Is Gold On a MASSIVE rally? (Ad)Gold has been on a tear this year. The yellow metal has hit an all-time high of $2,4231.29 recently and the rally could be far from over. From central banks to even Costco customers, it seems everyone is buying gold these days. With Wall Street watching the gold space carefully, now is a perfect time to pay attention to this stock. This Little known Company is a uniquely structured for profit ASND Media Mentions By Week ASND Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼0.310.55▲Average Medical News Sentiment ASND News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼154▲ASND Articles Average Week Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: JAZZ News Today ITCI News Today CERE News Today VKTX News Today LEGN News Today BPMC News Today CYTK News Today ELAN News Today IONS News Today OGN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASND) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHow Biden has already won 2024Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
